Systemic therapy for sarcomatoid renal cell carcinoma

Lance C. Pagliaro, Nizar Tannir, Kanishka Sircar, Eric Jonasch

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Renal cell carcinoma (RCC) is the most common malignant neoplasm of the kidney, and sarcomatoid RCC is an aggressive and lethal variant. Sarcomatoid features can be seen in all types of RCC and do not constitute a separate histologic type. No cellular or genetic biomarker for the sarcomatoid variant has yet been discovered. Most systemic therapies developed for metastatic RCC are less effective in sarcomatoid RCC, although some of the cytotoxic drugs may actually be more effective for sarcomatoid RCC because of its rapid rate of proliferation. Several ongoing prospective clinical trials are investigating new drug combinations for this disease.

Original languageEnglish (US)
Pages (from-to)913-920
Number of pages8
JournalExpert review of anticancer therapy
Volume11
Issue number6
DOIs
StatePublished - Jun 1 2011

    Fingerprint

Keywords

  • bevacizumab
  • chemotherapy
  • drug therapy
  • immunotherapy
  • kidney neoplasm
  • sarcomatoid neoplasm

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Pagliaro, L. C., Tannir, N., Sircar, K., & Jonasch, E. (2011). Systemic therapy for sarcomatoid renal cell carcinoma. Expert review of anticancer therapy, 11(6), 913-920. https://doi.org/10.1586/era.11.39